tiprankstipranks
Tectonic Therapeutic Advances in Pulmonary Hypertension Trials
Company Announcements

Tectonic Therapeutic Advances in Pulmonary Hypertension Trials

Pick the best stocks and maximize your portfolio:

Tectonic Therapeutic (TECX) has shared an update.

Tectonic Therapeutic, Inc. has announced the FDA’s clearance of its IND application for TX45, a promising treatment for Group 2 Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction. As the company progresses, investors and analysts can expect the release of Phase 1a clinical trial results in September 2024 and Phase 1b results by mid-2025. Furthermore, a global Phase 2 clinical trial is set to begin in the third quarter of 2024. This update signifies a significant milestone for Tectonic Therapeutic, potentially impacting its stock as it advances through the clinical trial phases.

For detailed information about TECX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyTectonic Therapeutic initiated with an Outperform at Raymond James
TipRanks Auto-Generated NewsdeskTectonic Therapeutic Inc. Faces Challenges with Australian Subsidiary Amid Regulatory and Operational Risks
TheFlyTectonic Therapeutic price target raised to $79 from $55 at Wells Fargo
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App